Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction
View Patent ↗The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
1. A method for treating a recalcitrant voiding dysfunction, the method comprising the step of injecting a botulinum toxin to a bladder wall of a patient with a recalcitrant voiding dysfunction, thereby treating the recalcitrant voiding dysfunction.
2. The method of claim 1 , wherein the patient is a human.
3. The method of claim 1 , wherein the patient is a human female.
4. The method of claim 1 , wherein the patient is a human male.
5. The method of claim 1 , wherein the botulinum toxin is a botulinum toxin type A.
6. The method of claim 1 , wherein a symptom of the recalcitrant voiding dysfunction is urinary incontinence.
7. A method for treating a recalcitrant voiding dysfunction, the method comprising the step of injecting a therapeutically effective amount of botulinum toxin type A to a bladder wall of a patient with a recalcitrant voiding dysfunction, thereby treating the recalcitrant voiding dysfunction.
8. The method of claim 7 , wherein the therapeutically effective amount of botulinum toxin type A is injected in the amount up to 2500 units.
9. The method of claim 7 , wherein the therapeutically effective amount of botulinum toxin type A is about 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A.
10. The method of claim 7 , wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.
11. The method of claim 7 , wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A.
12. A method for treating a recalcitrant voiding dysfunction in a patient in need thereof, the method comprising the step of administering a botulinum toxin type A, in an amount of up to 2500 units, to a bladder wall of a patient with a recalcitrant voiding dysfunction, thereby treating the recalcitrant voiding dysfunction of the patient with a recalcitrant voiding dysfunction.
13. The method of claim 12 , wherein the botulinum toxin type A is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a powder, a cream, an emulsion, a pill, a troche, a suppository, a suspension, and a solution.
14. The method of claim 12 , wherein administration of the botulinum toxin results in an increase in bladder capacity of the patient.
15. The method of claim 14 , wherein bladder capacity is increased to about 300 to 400 cubic centimeters post-administration.
16. The method of claim 12 , wherein the patient is a human.